Shire PLC (LON:SHP)‘s stock had its “buy” rating reissued by investment analysts at Goldman Sachs Group Inc. in a research report issued to clients and investors on Wednesday. They presently have a GBX 6,300 ($77.97) target price on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s target price would indicate a potential upside of 20.69% from the stock’s previous close.

SHP has been the topic of several other reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a GBX 6,300 ($77.97) price objective on shares of Shire PLC in a report on Tuesday, August 16th. BNP Paribas reaffirmed an “outperform” rating and set a GBX 5,700 ($70.54) price objective on shares of Shire PLC in a report on Wednesday, June 15th. Jefferies Group upped their price objective on shares of Shire PLC from GBX 6,050 ($74.88) to GBX 6,600 ($81.68) and gave the company a “buy” rating in a report on Wednesday, August 3rd. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Shire PLC in a report on Friday, July 22nd. Finally, Shore Capital reaffirmed a “buy” rating on shares of Shire PLC in a report on Tuesday, August 30th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and sixteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of GBX 5,828 ($72.13).

Analyst Recommendations for Shire PLC (LON:SHP)

Shire PLC (LON:SHP) opened at 5173.00 on Wednesday. The firm’s market capitalization is GBX 35.32 billion. The company has a 50-day moving average of GBX 5,001.78 and a 200 day moving average of GBX 4,587.48. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

The firm also recently declared a dividend, which was paid on Friday, October 7th. Shareholders of record on Thursday, September 8th were given a dividend of GBX 3.51 ($0.04) per share. This represents a yield of 0.07%. The ex-dividend date of this dividend was Thursday, September 8th.

In other Shire PLC news, insider Dominic Blakemore purchased 133 shares of Shire PLC stock in a transaction on Friday, September 30th. The shares were acquired at an average cost of GBX 5,010 ($62.00) per share, for a total transaction of £6,663.30 ($8,246.66).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with's FREE daily email newsletter.